Glenmark launches Tiotropium Bromide Dry Powder Inhaler in UK

15 Jun 2021 Evaluate

Glenmark Pharmaceuticals has launched bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand name - Tiogiva, in UK for the treatment of chronic obstructive pulmonary disease (COPD). COPD is a long-term condition that causes inflammation in the lungs, damaged lung tissue and a narrowing of the airways, making breathing difficult.

There are many different types of the condition, although little is known about what causes this variation and the best way to manage the different versions of the disease. According to data from IQVIA, Tiotropium DPI had a market size of $450 Million in the EU in the 12 month period ended September 2020.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

1966.05 -19.30 (-0.97%)
16-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1782.80
Dr. Reddys Lab 1279.00
Cipla 1500.00
Zydus Lifesciences 913.90
Lupin 2089.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×